Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany

Lung cancer is known for its high mortality; many patients already present with metastases at the time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes betwe...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 14; no. 1; pp. 16005 - 10
Main Authors: Tzschoppe, Therese, Ohlinger, Julia, Vordermark, Dirk, Bedir, Ahmed, Medenwald, Daniel
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 11.07.2024
Nature Publishing Group
Nature Portfolio
Subjects:
631/67
631/67/1059
631/67/1612
631/67/2324
631/67/322
692/308
692/308/174
692/308/409
692/4028
Adult
Aged
Aged, 80 and over
Cancer registry
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemotherapy
Female
Germany
Germany - epidemiology
Humanities and Social Sciences
Humans
Immunotherapy
Immunotherapy - methods
Kaplan-Meier Estimate
Lung cancer
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Metastases
Metastasis
Middle Aged
multidisciplinary
Neoplasm Metastasis
Non-small cell lung carcinoma
Population studies
Population-based studies
Radiation therapy
Science
Science (multidisciplinary)
Small cell lung carcinoma
Small Cell Lung Carcinoma - mortality
Small Cell Lung Carcinoma - pathology
Small Cell Lung Carcinoma - therapy
Survival
Survival Rate
Germany
Cancer registry
Survival
Lung cancer
Germany
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is known for its high mortality; many patients already present with metastases at the time of diagnosis. The aim of this study is to assess the impact of new treatment strategies on the survival of primarily metastatic lung cancer patients and to analyze the differences in outcomes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients. Population-based data, provided by the Robert-Koch Institute in Germany, was used and patients diagnosed between 2007 and 2018 were included in the study. We differentiated between NSCLC and SCLC patients and analyzed the survival over time for both sexes separately, using the Kaplan–Meier method. To evaluate survival advantages, we calculated multivariable hazard ratios. In total, 127,723 patients were considered for the study. We observed a moderate increase in survival over time. All patients showed an increased survival rate when undergoing chemotherapy. Minimal to no increase in survival was shown in NSCLC patients when receiving radiotherapy, whereas SCLC patients’ survival time did benefit from it. NSCLC patients receiving immunotherapy showed an increase in survival as well. It can be concluded that advancements in radiotherapy, the application of chemotherapy, and the introduction of immunotherapies lead to an increased survival time of both NSCLC and SCLC primarily metastatic lung cancer patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-66307-3